Clinical Research Directory
Browse clinical research sites, groups, and studies.
Poly-unsaturated Fats for Improving Nasal Polyps and Asthma
Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust
Summary
Asthma is a syndrome compromising many phenotypes including N-ERD (caused by increased 4-series leukotriene (LT) production). n-3 PUFA supplementation modulates 4-series LT and has anti-inflammatory effects. However, other than in a pilot study with dietary manipulation, the effects of N-ERD are unknown. The primary objective is to determine whether n-3 PUFA supplementation in people with N-ERD can improve asthma control using the asthma control questionnaire (ACQ-7). This is a placebo controlled randomised controlled parallel multicentre study with of 6g per day of PUFA for 6 months in people with N-ERD and poor asthma control
Official title: The Efficacy and Mechanisms of Action of n-3 Poly-unsaturated Fatty Acid Supplementation in People With Non-steroidal Exacerbated Airways Disease and Uncontrolled Asthma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2023-10-09
Completion Date
2026-01-31
Last Updated
2026-06-08
Healthy Volunteers
No
Conditions
Interventions
Fish oil
6g of EPA and DHA in a 1.3:1 ratio as six Omacor capsules manufactured by Provona Biocare (Olso Norway), or generic equivalent, taken once daily, or in divided doses, with food.
Placebo
Six capsules containing palm oil and soybean oil on an 8:2 ratio taken once daily, or in divided doses, with food.
Locations (1)
Norfolk and Norwich University Hospitals NHS Foundation Trust
Norwich, Norfolk, United Kingdom